Read review Dihexa for Autism Spectrum Disorder (ASD) The Campbell rs1858830 MET promoter C-allele autism finding (the strongest mechanistic anchor to Dihexa pharmacology), the January 2026 mGluR5 PET 16-23% lower availability, the December 2025 DAYBUE STIX (trofinetide) Rett approval, the March 2026 FDA leucovorin decision (CFD only, not autism), the 270,701 NHS open referrals breaching NICE NG142, and the ~700,000 UK autistic population
Please note that compounded medications are not reviewed by the FDA for safety, quality, or efficacy
Evaluation of interactions : This includes interactions with antimicrobial peptides, integrin signaling, and stemcellrelated markers in the context of tissue regeneration and matrix remodeling
Compounded medications are not approved by the FDA and have not been reviewed for safety, effectiveness, or quality
cloudiness indicates degradation Precipitation: Particulates signal protein denaturation discard immediately Temperature logs: Use a calibrated thermometer